This is the case of immunocytokine and antibody-drug conjugates (ADC) where pro-inflammatory payloads (e.g., IL2, IL12) and chemical cytotoxic agents can be delivered to the tumor niche, leading to low systemic adverse effects and potentiating their anti-cancer activity [124,125,126,127]. This evidence concerns the gene IL2 and cancer.